Taysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12

Taysha Gene Therapies (TSHA) will release its third-quarter 2026 financial results and host a corporate update call on November 12, 2026.

Rhea-AI Summary

Taysha Gene Therapies (TSHA) will release its third-quarter 2026 financial results and host a corporate update call on November 12, 2026.

The results cover the quarter ended September 30, 2026. The conference call and webcast begin at 8:30 AM Eastern Time, with an archived replay available on the company’s website.

Argus 15 min delay 7 alerts

-2.75% vs previous close $4.24 last price 1.6x rel. volume Open Argus

Details

Market Reaction – TSHA

$4.00 – $4.50 Day Range

$1.38B Mkt Cap at Last Price

On Nov 5, the day this news came out, the latest delayed price for TSHA is 2.75% below the previous close. Our momentum scanner has recorded 7 alerts for this stock so far that day. The latest delayed price is $4.24. Relative volume is above average at 1.6x what this stock usually trades by this time of day.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Terms

adeno-associated virus, monogenic diseases, central nervous system

3 terms

adeno-associated virus medical

"adeno-associated virus (AAV)-based gene therapies"

Adeno-associated virus (AAV) is a naturally occurring, small virus that researchers use as a safe carrier to deliver corrective genes into human cells, much like a specialized delivery van transporting instructions to a malfunctioning machine. It matters to investors because AAV-based therapies drive large development costs, unique manufacturing and regulatory risks, and the potential for high-value, one-time treatments that can significantly affect a biotech company’s future revenue and valuation.

monogenic diseases medical

"severe monogenic diseases of the central nervous system"

A monogenic disease is a medical condition caused by a harmful change in a single gene, where that single faulty instruction is enough to produce symptoms. For investors, these diseases matter because their clear genetic cause can make it easier for drug developers to design targeted therapies, diagnostics, or gene therapies, creating distinct clinical pathways, regulatory considerations, and potentially more predictable commercial opportunities—like fixing one broken line of code in a program.

central nervous system medical

"diseases of the central nervous system (CNS)"

The central nervous system (CNS) is the body's main control center, made up of the brain and spinal cord, that processes information and directs movement, sensation and basic functions like breathing. For investors, CNS-related products and research matter because they face long development times, strict safety testing and regulatory hurdles; success or failure can dramatically affect a company’s costs, timelines and potential market value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DALLAS, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the third quarter ended September 30, 2026, and host a corporate update conference call and webcast on Thursday, November 12, 2026, at 8:30 AM Eastern Time.

Participants may access the live webcast of the conference call from the Events and Presentations page of Taysha’s website at ir.tayshagtx.com. An archived replay of the webcast will be available on the Company’s website.

About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit http://www.tayshagtx.com.

Company Contact:
investors@tayshagtx.com

Media Contact:
media@tayshagtx.com